Literature DB >> 32042618

PD-L1 testing in urothelial carcinoma: are we there yet?

Geert J L H van Leenders1.   

Abstract

Entities:  

Year:  2019        PMID： 32042618      PMCID： PMC6989841          DOI： 10.21037/tau.2019.10.10

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  11 in total

1.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.

Authors:  Henning Reis; Rene Serrette; Jennifer Posada; Vincent Lu; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Gopa Iyer; Samuel A Funt; Min Yuen Teo; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie
Journal:  Am J Surg Pathol       Date:  2019-07       Impact factor: 6.394

2.  PD-L1 Antibody Comparison in Urothelial Carcinoma.

Authors:  Maud Rijnders; Astrid A M van der Veldt; Tahlita C M Zuiverloon; Katrien Grünberg; Erik Thunnissen; Ronald de Wit; Geert J L H van Leenders
Journal:  Eur Urol       Date:  2018-11-27       Impact factor: 20.096

3.  Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

Authors:  Maria Tretiakova; Regan Fulton; Masha Kocherginsky; Thomas Long; Cigdem Ussakli; Tatjana Antic; Allen Gown
Journal:  Mod Pathol       Date:  2017-12-22       Impact factor: 7.842

4.  Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.

Authors:  Michelle R Downes; Elzbieta Slodkowska; Nora Katabi; Achim A Jungbluth; Bin Xu
Journal:  Histopathology       Date:  2019-09-09       Impact factor: 5.087

5.  PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.

Authors:  Anjelica Hodgson; Elzbieta Slodkowska; Achim Jungbluth; Stanley K Liu; Danny Vesprini; Danny Enepekides; Kevin Higgins; Nora Katabi; Bin Xu; Michelle R Downes
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

6.  Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.

Authors:  Chiyun Wang; Elan Hahn; Elzbieta Slodkowska; Antoine Eskander; Danny Enepekides; Kevin Higgins; Danny Vesprini; Stanley K Liu; Michelle R Downes; Bin Xu
Journal:  Hum Pathol       Date:  2018-08-01       Impact factor: 3.466

7.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

8.  Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.

Authors:  Joep J de Jong; Hans Stoop; Daan Nieboer; Joost L Boormans; Geert J L H van Leenders
Journal:  Histopathology       Date:  2018-09-25       Impact factor: 5.087

9.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Authors:  Thomas Powles; Peter H O'Donnell; Christophe Massard; Hendrik-Tobias Arkenau; Terence W Friedlander; Christopher J Hoimes; Jae Lyun Lee; Michael Ong; Srikala S Sridhar; Nicholas J Vogelzang; Mayer N Fishman; Jingsong Zhang; Sandy Srinivas; Jigar Parikh; Joyce Antal; Xiaoping Jin; Ashok K Gupta; Yong Ben; Noah M Hahn
Journal:  JAMA Oncol       Date:  2017-09-14       Impact factor: 31.777

10.  Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.

Authors:  Kristina Schwamborn; Johannes U Ammann; Ruth Knüchel; Arndt Hartmann; Gustavo Baretton; Felix Lasitschka; Peter Schirmacher; Till Braunschweig; Robert Tauber; Franziska Erlmeier; Stefanie Hieke-Schulz; Wilko Weichert
Journal:  Virchows Arch       Date:  2019-07-02       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.